Clinical Trials Logo

Tumors or Premalignant Lesions clinical trials

View clinical trials related to Tumors or Premalignant Lesions.

Filter by:
  • None
  • Page 1

NCT ID: NCT02821494 Completed - Clinical trials for Tumors or Premalignant Lesions

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

Start date: March 2015
Phase: Phase 1
Study type: Interventional

A phase I study to establish the highest safe dose that induces HPV16 E6-specific T-cell responses, using the highly promising novel therapeutic vaccine concept named: Hespecta (HPV E Six Peptide Conjugated To Amplivant®) to induce HPV16 E6-specific T-cell responses.